XENON PHARMACEUTICALS INC. (XENE) Operating income 2016–2025
XENON PHARMACEUTICALS INC. (XENE) annual operating income history from SEC filings — each fiscal year as reported.
-$373.1MFY2025 · since FY2016: -$24.8M → -$373.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$373.1M | -33.6% |
| FY2024 | -$279.3M | -30.5% |
| FY2023 | -$214.1M | -65.7% |
| FY2022 | -$129.1M | -63.5% |
| FY2021 | -$79.0M | -152.4% |
| FY2020 | -$31.3M | +26.9% |
| FY2019 | -$42.8M | -12.6% |
| FY2018 | -$38.0M | -16.8% |
| FY2017 | -$32.6M | -31.3% |
| FY2016 | -$24.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More XENE financial trends
XENE RevenueXENE Net incomeXENE Net marginXENE Gross profitXENE Gross marginXENE Operating marginXENE Operating cash flowXENE Free cash flowXENE Capital expendituresXENE Return on equityXENE Stock buybacksXENE Dividends paidXENE Total assetsXENE Total liabilitiesXENE Shareholders’ equityXENE overview →